Work Here?
Overview
DocMorris AG runs an online health ecosystem that connects patients with doctors, pharmacies, and insurers. It operates an online pharmacy for prescription and OTC medications, a health marketplace for partner products, and TeleClinic for online medical consultations, all within a single digital platform. Patients can manage e-prescriptions, order medications, access health and personal care products, and receive telemedicine services, supported by AI tools and health assessments. The company differentiates itself by integrating pharmacy, telemedicine, and insurer partnerships into one seamless platform, backed by automated logistics in the Netherlands and an in-house retail media arm (dmr Advertising) to support profitability. Its goal is to guide users through the entire health journey—from symptom awareness and diagnosis to treatment and ongoing monitoring—while expanding across European markets.
About DocMorris
Industries
Data & Analytics
Consumer Software
Enterprise Software
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Frauenfeld, Switzerland
Founded
1993
Get referred to DocMorris
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 external revenue rose 15.2%, with Rx up 45.8%.
- DocMorris added 12.9 million active customers by July 2026.
- Management targets EBITDA break-even in 2026 and free cash flow break-even in 2027.
What critics are saying
- Hamburg's June 23, 2026 ruling blocked DocMorris' Rx-gutschein campaign under HWG.
- June 2026 layoffs and Ludwigshafen closure signal persistent margin pressure through 2027.
- Redcare Pharmacy and German chains can squeeze DocMorris before EBITDA break-even.
What makes DocMorris unique
- DocMorris' Heerlen automation moat supports faster Rx fulfillment than German stores.
- TeleClinic, retail media, and marketplace drove 80% digital-services growth in Q2 2026.
- DocMorris' Dutch base still enables German Rx bonus offers against local competitors.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$499.2M
Above
Industry Average
Funded Over
0 Rounds
Stock Price
Company News
DocMorris, a leading online pharmacy serving 11 million active customers, has partnered with Algolia to transform its digital commerce experience using AI-powered search technology. The implementation has driven branded sales up 156% and overall net sales up 147%. The company replaced its legacy search system with Algolia's AI Search and Retrieval platform to better navigate its catalogue of over 150,000 products across 195 million web page visits. DocMorris leverages Algolia's Dynamic Re-Ranking, which automatically surfaces relevant products based on real customer behaviour. Since implementation, DocMorris has achieved a 160% increase in sessions using search, 112% increase in conversions, and 147% lift in net sales. The platform's millisecond response times help customers quickly find the right medicine when needed.
DocMorris Versandapotheke revolutionizes online pharmacy access in Europe: key developments and investor opportunities. 02.04.2026 - 15:58:15 | ad-hoc-news.de DocMorris, Europe's leading online pharmacy platform under ISIN CH0042615283, continues to expand its digital health services, offering North American investors exposure to the booming telepharmacy and e-commerce healthcare sector amid rising demand for convenient medication delivery. DocMorris Versandapotheke stands at the forefront of Europe's digital pharmacy transformation, delivering prescription and over-the-counter medications directly to consumers' doors with unmatched efficiency and regulatory compliance. As online health services gain traction post-pandemic, this platform's strategic expansions and technological integrations make it commercially vital, providing North American investors a gateway to the high-growth European e-pharmacy market projected to exceed €50 billion by 2028. As of: 02.04.2026 By Dr. Elena Hartmann, Healthcare Investment Analyst: DocMorris exemplifies how digital innovation is reshaping pharmacy retail, positioning it as a resilient player in a market where convenience meets stringent health regulations. Current landscape: DocMorris' dominant position in digital pharmacy. DocMorris Versandapotheke operates as a fully licensed online pharmacy, serving millions across Germany, Switzerland, and other European nations. The platform integrates seamless prescription uploads, automated approvals, and rapid delivery, addressing key pain points in traditional pharmacy models. Recent enhancements include AI-driven personalization for medication recommendations and subscription models for chronic condition management. These features have driven user retention rates above 70%, underscoring the platform's sticky customer base. In 2025, DocMorris reported a 25% year-over-year increase in active users, fueled by partnerships with major health insurers. This growth trajectory highlights its relevance in today's health-conscious economy. Official source The official product page or announcement offers the most direct context for the latest development around DocMorris Versandapotheke. Strategic expansions driving revenue growth. DocMorris has aggressively expanded its footprint, launching services in new markets like Belgium and the Netherlands. These entries leverage the company's centralized logistics network, capable of handling over 10 million parcels annually. Key to this growth is the integration of telehealth consultations, allowing users to consult doctors online before ordering. This end-to-end service model reduces abandonment rates and boosts average order values by 15%. Investors note the platform's focus on generics and private-label products, which offer higher margins than branded pharmaceuticals. This strategy has improved EBITDA margins to 12% in recent quarters. Technological edge in e-pharmacy operations. At the core of DocMorris' success is its proprietary pharmacy management system, which automates 90% of prescription verifications. Blockchain technology ensures tamper-proof supply chain tracking, enhancing trust and compliance. The mobile app, available in multiple languages, features real-time tracking and AR-based medication identification. User feedback rates it 4.8/5 on app stores, reflecting superior UX design. Future roadmaps include drone delivery pilots in urban areas and AI chatbots for 24/7 customer support, positioning DocMorris ahead of competitors like Shop Apotheke. Regulatory compliance and market barriers. Operating under strict EU pharmaceutical regulations, DocMorris holds licenses from multiple national authorities, including the German Federal Institute for Drugs and Medical Devices. This compliance creates high entry barriers for newcomers. Recent regulatory approvals for cross-border prescriptions have unlocked additional revenue streams. The company invests heavily in data privacy, adhering to GDPR standards that surpass many peers. For North American investors, this regulatory moat translates to predictable growth in a fragmented market dominated by offline players. Financial performance and growth metrics. DocMorris has consistently outperformed revenue forecasts, with 2025 sales reaching €1.2 billion, up 30% from prior year. Gross merchandise value (GMV) surged due to increased basket sizes during flu seasons and chronic care campaigns. Cash flow from operations supports ongoing investments without diluting shareholders. Debt levels remain manageable at 1.5x EBITDA, providing flexibility for acquisitions. Key metrics include a 40% customer acquisition cost reduction via digital marketing and a lifetime value exceeding €500 per user. Investor context: exposure to European healthcare boom. Listed under ISIN CH0042615283 as part of DocMorris AG, the stock offers North American investors diversified exposure to Europe's digital health shift. Trading on the SIX Swiss Exchange, it benefits from stable Swiss regulatory oversight. Valuation multiples trade at a discount to U.S. e-commerce peers, with a forward P/E of 18x versus sector averages of 25x. Analyst consensus points to 20-30% upside based on market penetration potential. Dividend yields, though modest at 1.2%, signal confidence in free cash flow generation amid expansion. Competitive landscape and future catalysts. DocMorris competes with Zuellig Pharma and local chains but leads in online penetration at 15% market share in core markets. Strategic alliances with insurers cover 60% of prescriptions, locking in recurring revenue. Upcoming catalysts include a pan-European prescription harmonization push and entry into the UK post-Brexit adjustments. Sustainability initiatives, like eco-friendly packaging, appeal to millennial consumers. North American investors should monitor quarterly earnings for updates on user growth and margin expansion, key drivers of long-term value creation. Disclaimer: Not investment advice. Stocks are volatile financial instruments. Der Trick, mit dem IT-Profis Windows 11 auf "inkompatiblen" PCs installieren. Gratis-Report vom 04. April: Offiziell nicht unterstützt, inoffiziell problemlos möglich: Windows 11 läuft auf fast jedem PC der letzten 10 Jahre. Der kostenlose Report enthüllt die Methode, die auch Microsoft-Mitarbeiter nutzen - inklusive Anleitung für den sicheren Umstieg. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. CH0042615283 | DOCMORRIS VERSANDAPOTHEKE | boerse | 69057429 |
A more personal digital health experience for people in Europe. Mar 19, 2026 Headway Information Services Pty is partnering with DocMorris, one of Europe's leading online pharmacies, to create a true digital health companion. Dr. Susan Thomas Director, Google for Health Listen to article 2:34 minutes From understanding symptoms to managing prescriptions, navigating healthcare isn't always straightforward. Technology can help make it simpler and more personal. That's why Headway Information Services Pty is partnering with DocMorris, one of Europe's leading online pharmacies, to help build a more intuitive and supportive digital health experience. Headway Information Services Pty is using its technology to support DocMorris in their AI-first transformation, with the goal of creating a true digital health companion for millions of people together. This means combining DocMorris' deep healthcare and pharmaceutical expertise with a range of Google's tools - from the AI capabilities in its Gemini models and the secure foundation of Google Cloud to the helpfulness of Google Ads and Google for Health. Making healthcare easier, from start to finish. Its work will focus on making everyday health needs simpler and more accessible. Key areas will include: * A personal health guide: Using its AI tools, DocMorris is developing a digital companion to help people get support and assistance all the way from symptom onset to redeeming an e-prescription. * A helpful online pharmacy: Conversational AI will help make the online pharmacy shopping experience more intuitive and personalized for DocMorris' 11 million active customers. * A secure and private experience by design: DocMorris is migrating its infrastructure to Google Cloud. This ensures that personal health data is processed securely within EU data centers, meeting leading security standards, while giving DocMorris full control over its data. "At its core, our transformation is all about the patient," says Walter Hess, CEO of DocMorris. "By using Google's world-class AI infrastructure, we are giving individuals direct, secure access to their own health journeys through a personalized and intuitive experience. We have intentionally chosen Google as our partner because they enable us to maintain full digital sovereignty while meeting the highest requirements for data privacy and security." Headway Information Services Pty believe technology can play a powerful role in making healthcare more accessible. Headway Information Services Pty look forward to continuing its work with DocMorris to help build the future of digital health together. POSTED IN:
DocMorris launches new ai-powered Prescription Service across DACH region amid digital health boom. 18.03.2026 - 12:24:22 | ad-hoc-news.de DocMorris online pharmacy introduces an innovative AI-driven tool for instant prescription renewals, targeting 15 million users in Germany, Austria, and Switzerland with faster access and reduced wait times. DocMorris has rolled out its latest AI-powered prescription renewal service, enabling customers in the DACH region to receive approvals in under 60 seconds without traditional pharmacy visits. This launch addresses surging demand for digital health solutions as aging populations and chronic disease rates climb, positioning the service as a commercial game-changer for online pharmacies. DACH investors should note how this strengthens DocMorris' market lead in Europe's largest e-pharmacy market, potentially driving revenue growth amid regulatory tailwinds. As of: 18.03.2026 By Dr. Elena Voss, Senior HealthTech Analyst: DocMorris' AI prescription tool exemplifies how digital innovation is reshaping patient access in Europe's fragmented pharmacy sector. AI Prescription Service hits the market. The new service integrates machine learning algorithms trained on millions of anonymized patient records to assess renewal eligibility instantly. Users upload photos of existing prescriptions via the DocMorris app, and the AI cross-references dosage history, drug interactions, and regulatory guidelines. Approvals come with digital barcodes scannable at partner pharmacies or for direct home delivery, cutting processing from days to seconds. This rollout follows two years of beta testing in Switzerland, where it achieved 98% accuracy rates and 40% uptake among chronic medication users. Germany sees the biggest initial push, with 5 million app users targeted in Q1 2026. Official source The official product page or announcement offers the clearest direct context around the latest development for DocMorris AI Prescription Service. Expansion to Austria begins next month, leveraging DocMorris' existing 2.5 million customer base there. Swiss users gain priority access due to favorable e-health regulations. The service excludes controlled substances and new prescriptions, focusing on renewals for hypertension meds, statins, and antidiabetics - top categories representing 60% of pharmacy volumes. Technical backbone and user experience. Powered by a proprietary neural network developed in-house, the AI scans for anomalies like dosage escalations or contraindications with pharmacies' real-time inventory data. Blockchain secures patient data transmission, ensuring GDPR compliance across borders. App integration includes voice commands for elderly users and multilingual support in German, French, and Italian. Early metrics show 75% of trials completed in 45 seconds, versus 20 minutes at physical counters. DocMorris invested 25 million euros in R&D, partnering with ETH Zurich for algorithm refinement. Reactions and market mood Feedback highlights seamless onboarding, with 92% user satisfaction in pilot phases. Future updates promise integration with wearable devices for auto-refills based on vitals. Commercial impact in DACH pharmacy landscape. Europe's online pharmacy market hits 35 billion euros annually, with DACH accounting for 45% due to high internet penetration and dense populations. DocMorris commands 28% share in Germany, where 22 million citizens rely on chronic meds. This service could lift repeat order rates by 35%, as convenience trumps in-person hassles. Cost savings pass to consumers via 12% average discounts on bundled deliveries. Competitors like Shop-Apotheke lag with manual reviews, giving DocMorris a first-mover edge. Projected Q2 revenue boost: 18 million euros from 1.2 million new service users. Partnerships with 4,000 brick-and-mortar pharmacies expand reach without inventory overhead. Regulatory green lights and barriers overcome. German BfArM approved the AI model after rigorous audits, certifying it matches human pharmacists' accuracy. Austria's BASG followed suit, praising data privacy measures. Switzerland's Swissmedic expedited clearance under its digital health sandbox. Challenges included harmonizing three nations' drug codes and prescription laws. DocMorris lobbied for EU-wide e-prescription standards, accelerating adoption. Patient advocacy groups endorse the tool for reducing access disparities in rural areas. Patient demographics and adoption drivers. Prime targets: 55+ age group, managing diabetes (4.1 million Germans) and cardiovascular issues. Young professionals seek time savings, with 40% urban millennials testing in first week. Post-pandemic telehealth familiarity boosts uptake by 50% versus pre-2020 levels. Marketing via targeted app notifications yields 22% conversion. Integration with public health apps like Germany's ePA enhances trust. Rural penetration addresses pharmacy deserts, where 15% of Germans live over 10km from outlets. Competitive edge and scalability plans. Unlike Zuellig Pharma's wholesale focus, DocMorris prioritizes B2C digital. AI scalability allows pan-EU rollout by 2027, eyeing Netherlands and Spain. Cost per renewal drops to 0.45 euros versus 2.10 for manual. Subscription model for unlimited renewals at 9.99 euros/month pilots in Berlin. Analytics from service feed personalized recommendations, upselling OTC products 28%. Further reading You can find additional reports and fresh developments around DocMorris AI Prescription Service in the current news overview. Investor context for DocMorris shares. DocMorris AG (CH0042615283) trades on SIX Swiss Exchange, reflecting e-pharmacy pressures with shares near 52-week lows around 4.30 CHF. This product launch offers a clear growth catalyst amid analyst targets averaging 12.71 CHF. DACH funds eye the 78% free float for liquidity, with cashflow improvements expected from efficiency gains. Monitor Q1 earnings for service uptake metrics. Disclaimer: Not investment advice. Stocks are volatile financial instruments. Ihr PC erfüllt die Windows 11 Anforderungen nicht? Dieses Gratis-Paket vom 26. März zeigt den Ausweg: Microsoft blockiert Windows 11 auf älteren PCs - aber es gibt einen legalen Weg. Das kostenlose Paket zeigt Schritt für Schritt, wie Sie die Systemanforderungen umgehen und Windows 11 trotzdem installieren. Ohne Risiko, ohne Datenverlust. So schätzen börsenprofis die Aktie DocMorris Versandapotheke ein. Verpasse keine chance mehr. Ob Chancen, Risiken oder neue Signale zur Aktie DocMorris Versandapotheke: trading-notes liefert dir seit 2005 dreimal pro Woche verlässliche Aktien-Impulse zu diesem und vielen weiteren spannenden Aktien-Werten - dreimal pro Woche kostenlos per E-Mail. Für. Immer. Kostenlos. CH0042615283 | DOCMORRIS VERSANDAPOTHEKE | boerse | 68784668 |
Advestra advised Bank of America and UBS as joint bookrunners on DocMorris' placement of CHF 49.6 million convertible bonds due 2028 and its public repurchase offer for CHF 87.6 million outstanding convertible bonds due 2026. The Advestra team included Annette Weber, Thomas Reutter, Mariëlle van Nimwegen and Jana Wildberger on capital markets matters, along with Céline Martin on tax.
There are no jobs for DocMorris right now.
Find jobs on Simplify and start your career today
About DocMorris
Industries
Data & Analytics
Consumer Software
Enterprise Software
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Frauenfeld, Switzerland
Founded
1993
There are no jobs for DocMorris right now.
Find jobs on Simplify and start your career today